WAYNE, Pa., June 18 /PRNewswire-FirstCall/ -- Escalon Medical Corp.
(Nasdaq: ESMC) Escalon made an exchange offer for the shares of Drew
Scientific Group PLC (London Stock Exchange: DRW), a diagnostics company that
specializes in analytical systems for laboratory testing worldwide.  The
threshold level of acceptances of Drew Scientific shareholders has not been
achieved to date as required in the exchange offer agreement.  Therefore,
Escalon has extended the termination date of the offer until 3:00 p.m. (London
time) on Friday, July 2, 2004.
    Drew Scientific, with manufacturing operations in Texas and Connecticut,
is a diagnostics company specializing in the design, manufacture, sale and
distribution of analytical systems for laboratory testing worldwide.  Drew
Scientific provides instrumentation and consumables for the diagnosis and
monitoring of medical disorders in the areas of diabetes, cardiovascular
diseases and hematology, as well as Veterinary hematology and blood chemistry.

    Founded in 1987, Escalon develops, markets and distributes ophthalmic
diagnostic, surgical and pharmaceutical products as well as vascular access
devices.  Escalon seeks to further diversify its product line to achieve
critical mass in sales and take better advantage of Escalon's distribution
capabilities through internal product development, acquisitions or strategic
partnerships.  Escalon has headquarters in Wayne, Pennsylvania and
manufacturing operations in Long Island, New York and New Berlin, Wisconsin.

    To U.S. Holders of Drew Scientific Shares:
    This intention to make a tender offer is made for the securities of a
foreign company.  The offer is subject to disclosure requirements of a foreign
country that are different from those of the United States.  Financial
statements included in the document, if any, have been prepared in accordance
with foreign accounting standards that may not be comparable to the financial
statements of United States companies.
    It may be difficult for you to enforce your rights and any claim you may
have arising under the federal securities laws, since Drew Scientific is
located in a foreign country, and some or all of its officers and directors
may be residents of a foreign county.  You may not be able to sue a foreign
company or its officers or directors in a foreign court for violations of the
U.S. securities laws.  It may be difficult to compel a foreign company and its
affiliates to subject themselves to a U.S. court's judgment.
    You should be aware that Escalon may purchase securities otherwise than
under the tender offer, such as in open market or privately negotiated
purchases.

    Note:  This press release contains statements that are considered
forward-looking under the Private Securities Litigation Reform Act of 1995,
including statements about Escalon's future prospects.  They are based on
Escalon's current expectations and are subject to a number of uncertainties
and risks, and actual results may differ materially.  The uncertainties and
risks include whether Escalon is able to improve upon the operations of
Escalon's business units, generate cash and identify, finance and enter into
business relationships and acquisitions, uncertainties and risks related to
new product development, commercialization, manufacturing and market
acceptance of new products, marketing acceptance of existing products in new
markets, research and development activities, including failure to demonstrate
clinical efficacy, delays by regulatory authorities, scientific and technical
advances by Escalon or third parties, introduction of competitive products,
third party reimbursement and physician training as well as general economic
conditions.  Further information about these and other relevant risks and
uncertainties may be found in Escalon's report on Form 10-K, and its other
filings with the Securities and Exchange Commission, all of which are
available from the Commission as well as other sources.

Link to this page: